Itaconic Acid Market Incredible Possibilities, Growth Analysis and Forecast To 2025 |Alpha Chemika, Chengdu Jinkai Biology Engineering, Itaconix…

September 21, 2020 medical

Overview Of Itaconic Acid Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Itaconic Acid Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Itaconic Acid Market competition by top manufacturers as follow: , Alpha Chemika, Chengdu Jinkai Biology Engineering, Itaconix Corporation, Jinan Huaming Biochemistry, Shandong Zhongshun Science & Technology Development, Spectrum Chemical, Zhejiang Guoguang Biochemistry, Nanjing Huajin Biologicals, Qingdao Langyatai Group, Qingdao Kehai Biochemistry, Ronas Chemicals, Shandong Kaison Biochemical,

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/141740

The global Itaconic Acid market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: SynthesisFermentation

Market Segment by Applications, covers:PlasticizerLubricating Oil AdditiveOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/141740

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Itaconic-Acid-Market-141740

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Biochemistry

CSU-SACNAS working to create inclusive community in STEM – College of Natural Sciences – Source

September 21, 2020 medical

Taking a leadership role

Ricardo Vazquez, a fifth-year CSU student double majoring in biochemistry and molecular biology and biomedical science, is this years SACNAS president. He has been involved with the club since 2018 and joined immediately after transferring from Aims Community College in Greeley.

What drew him to the club, initially, was diversity.

Not everybody in SACNAS identifies as Chicano or is Hispanic or Native American, said Vazquez who identifies as Chicano and is a first-generation student. I really like the community because its not a student organization dedicated to promoting just one under-represented minority, it is an enginWoverarching student organization dedicated to promoting diversity in STEM by allowing underrepresented students the opportunity to have an impact in both their scientific and cultural communities.

Vazquez added: I never thought Id be the president of a student organization I never even thought Id be centered in anything. I really didnt have a community back at my old school. I came to CSU looking to be part of a community, and SACNAS really allowed me to do that. Now, the club is allowing me to take a leadership role, trying to grow it and get everybody take part in the community.

SACNAS has a robust group of advisors, faculty board members, and long-term members who are passionate about science and fostering the success of all people in STEM.

Vazquez added that being part of a community of support has been a tremendous asset, adding that SACNAS is a hub for rewarding mentorship opportunities.

Building a community that empowers us and allows us to ask for help and ask questions and be mentors for each other is really important, because you dont know what you dont know, and there are people in our community that do know and want to help, Vazquez said.

Vazquez found SACNAS through Paul Laybourn, a professor in the Department of Biochemistry and Molecular Biology and advisor for the club.

Diversity and inclusion are the biggest issues in science today, Laybourn said. They are a bigger problem than funding. Diversity and inclusion affect science. Its a national security issue. If you dont have all ideas and minds at the table how can you be prepared to solve problems, to answer questions?

While SACNAS was initially meant to bring representation to a few minority groups, it has evolved to become inclusive of all minoritized groups in STEM.

We want everyone to succeed, Vazquez said. SACNAS main goal is getting students more involved in research so that they can understand fundamentally what its like to be a researcher, Laybourn said. We also seek to create a scientific community that doesnt ask you to adopt a new culture but rather introduce your culture to your research.

SACNAS is also diverse in the disciplines of science it represents. It allows students to speak to each other about their research, which teaches them to communicate about their work outside of their direct field, which is a huge skill, said Shane Kanatous, the SACNAS faculty advisor and Department of Biology professor.

While CSU has many different administrative and student efforts focused on diversity and inclusion, SACNAS is somewhat unique. Everyone in science is big on research, but not everyone is big on diversity and inclusion, said CSU student Vincent Elias, a neuroscience major and the public and marketing relations officer for SACNAS.

This semester, all SACNAS events and meetings will be completely virtual. The club leaders have developed We Hear You, Lets Talk About It, a virtual meeting series in response to the COVID-19 pandemic that provides a safe space for community members designed to foster discourse and support.

According to the organizers, the first few iterations of the meeting have been very successful, and the club leadership is looking forward to growing the community, even in a virtual format.

The club has also taken the time to develop a statement of commitment: To promote diversity within STEM with careful consideration of the Black Lives Matter movement and incidents of racial bias both on and off CSUs campus.

The action we take on campus will prepare us to take action off campus, said Vazquez.

This years SACNAS student leaders give proof that the organization is deeply committed to its mission, and ready to make change at CSU, in STEM, and around the world.

About Rams Shape Science:Meet some of the extraordinary students, faculty, and staff in the College of Natural Sciences who are shaping the future of science and our society.

More:
CSU-SACNAS working to create inclusive community in STEM - College of Natural Sciences - Source

Cell Biology

Researchers identify a compound that inhibits growth of schwannomas – News-Medical.Net

September 21, 2020 medical

Reviewed by Emily Henderson, B.Sc.Sep 21 2020

Schwannomas are tumors of the peripheral nervous system, which often occur in the genetic disease neurofibromatosis type 2.

The research group of Prof. Dr. Helen Morrison at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, identified a compound that inhibits the growth of such tumors and improves nerve function.

In a new project, the group will now conduct a multi-center preclinical study together with three German partners. The BMBF is funding this step towards a therapeutic application with a grant of 1.45 million euro over 3 years.

Jena. A schwannoma is a benign tumor of the peripheral nervous system. It usually results from an abnormal overgrowth of Schwann cells, a cell type covering nerve fibers and supporting them in their function.

Following nerve damage, Schwann cells divide to support regeneration in sufficient numbers. However, if cell division is not limited in time, over-proliferation of Schwann cells occurs and causes schwannoma formation.

These progressively growing tumors compress nerve cells, impairing nerve function and causing symptoms such as paralysis or pain.

Schwannomas often appear in the context of the hereditary disease neurofibromatosis type 2 (NF2), which causes uncontrolled growth of nervous and connective tissues, particularly surrounding the 8th cranial nerve. Consequently, loss of hearing and balance are frequent symptoms of NF2.

Prof. Dr. Helen Morrison and her research group "Nerve Regeneration" at the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, is studying the role of Schwann cells in the peripheral nervous system.

The team was able to identify a molecule that inhibits schwannoma growth. The protein Neuregulin 1 (Nrg1) occurs naturally in the body and induces differentiation of Schwann cells, including termination of cell division following nerve regeneration.

However, in the case of the hereditary disease NF2 and likely other schwannomas, Nrg1 is strongly downregulated. Without this stop signal, Schwann cells fail to differentiate, continue to divide and form schwannomas.

Therapy options are very limited and focus on surgical removal, often causing additional nerve damage and entailing a high recurrence rate. Novel approaches are urgently needed to improve tumor therapy and patient's quality of life.

Prof. Dr. Morrison's group has already shown that Nrg1 inhibits schwannoma growth and improves nerve function in a mouse model.

Her current project aims to develop this approach further towards clinical application. Previous studies on heart diseases have classified Nrg1 as safe for use in humans.

Now, the research group has successfully obtained funding to conduct a multi-centric, preclinical study. Starting from August 2020, the German Federal Ministry of Education and Research (BMBF) will fund this study for 3 years with a total sum of 1.45 million euro, of which approximately 732,000 euro will go to FLI.

We are very pleased about this support and see this as encouragement of our research," says Prof. Morrison, who has many years of experience in research on the hereditary disease NF2. "Together with our partners we hope to contribute to the development of a drug to help people affected by this disease."

Headed by Prof. Dr. Morrison of the FLI, the research team also includes the partner laboratories of Dr. Robert Fledrich and Dr. Ruth Stassart of the University Hospital Leipzig and Prof. Dr. Reinhard Bauer at the Institute of Molecular Cell Biology of Jena University Hospital.

The teams' research approach is unprecedented: Following standards of clinical patient trials, three centers will conduct parallel, randomized and blinded experiments following a preregistered study protocol.

Study design as well as statistical data analysis is conducted independently by the team of Prof. Dr. Andr Scherag of the Institute for Medical Statistics, Computer and Data Sciences of Jena University Hospital. Collectively, these measures strongly increase the studies' validity and significance.

The research network will be further supported by a funded membership of the TMF (Technologie- und Methodenplattform fr die vernetzte medizinische Forschung e.V.), that will enable a broad exchange with experts on diverse methods crucial to networked medical research (e.g. research data management).

Additionally, all projects of the current BMBF funding line will be counseled by the partner project "DECIDE" located at the Charit in Berlin.

We are looking forward to the interaction with all these different experts to apply highest standards to our preclinical study."

Dr. Helen Morrison, Professor, Leibniz Institute on Aging - Fritz Lipmann Institute

The new BMBF funding line for preclinical studies supports innovative research projects aiming to expedite translation of important research findings from basic research to clinical application. This aim is shared by the [emailprotected] program, which supported the preceding work leading up to the current preclinical study.

Dr. Sonja Schtzlein, head of [emailprotected], sees the current funding as a success: "I am pleased to see that SPARK has contributed to advancing the project to this important step towards an application-oriented therapy by providing financial support, advice and arranging mentoring partners from industry."

Continued here:
Researchers identify a compound that inhibits growth of schwannomas - News-Medical.Net

Cell Biology

Enhancing overall facial skin wellness: Augustinus Bader reveals The Face Oil – The Moodie Davitt Report – The Moodie Davitt Report

September 21, 2020 medical

Augustinus Bader is a Silver Partner of The Moodie Davitt Virtual Travel Retail Expo where it is exhibiting in #Virtual Stand BT-S9

Augustinus Bader a Silver Partner at the upcoming Moodie Davitt Virtual Travel Retail Expo has extended its luxury skincare range with The Face Oil.

The new Face Oil offers an ultra-lightweight, fast-absorbing and nourishing formula made with an exact calibration of cold-pressed oils and the brands patented TFC8 technology.

Augustinus Bader is a London-based science-driven premium skincare brand. It was launched in 2018 to help fund research into burn repair, skin graft prevention and scar minimisation.

The brand was founded by Professor Augustinus Bader who is a pioneer in the field of stem cell biology. Backed by more than 30-years of research and innovation, Bader developed a ground-breaking wound-gel in 2008 that helped regenerate skin affected by third-degree burns without surgery.

The Face Oil leverages Professor Augustinus Baders extensive stem cell biology expertise. It instantly hydrates the skin and retains moisture without leaving any greasy residue. It also minimises fine lines and wrinkles, reduces hyper-pigmentation and boosts cellular renewal.

The Face Oil offers a powerful blend of Babassu Oil, Argan Oil, Hazelnut Oil, Karanja Oil and TFC8

The Face Oil is made with a potent blend of Babassu Oil, Argan Oil, Hazelnut Oil, Karanja Oil and TFC8. Babassu Oil is a vitamin-rich seed oil which protects the skin against environmental aggressors, while Argan oil helps restore the skins hydrolipidic film and prevents trans-epidermal water loss.

Hazelnut Oil supports the skins moisture retention, while Karanja Oil delivers soothing antimicrobial properties and prevents premature ageing. Finally, TFC8 an exclusive patented complex of amino acids and vitamins boots internal skin repair and renewal.

We wanted to offer our customers the option between a rich cream, a light cream, and now, an oil, so they can select the texture that works best for their facial skincare routine, commented Professor Bader. Each of these offerings contains our specialised compound TFC8, which transport natural mechanisms for skin repair. As long as you have one product with TFC8, you will see results.

Augustinus Bader officially launched The Cream and The Rich Cream in 2018. The brand made its travel retail debut at TFWA World Exhibition in Cannes in 2019 and plans to further extend its footprint in the channel at the upcoming Moodie Davitt Virtual Travel Retail Expo this October, where it is exhibiting at #Virtual Stand BT-S9.

Professor Augustinus Bader leverages more than 30 years of stem cell biology expertise to formulate his luxury skincare range

Augustinus Bader is a Silver Partner at the inaugural Moodie Davitt Virtual Travel Retail Expo.

The unique 5-day live event, followed by a 30-day showcase, begins on 12 October, just after the conclusion of the Chinese Golden Week holidays. It features a star-studded series of events across the five days, including a Symposium, category workshops and a new consumer research initiative.

Registration is free for buyers, exhibitors and preferred media partners. (Clickhereto register)

Read the rest here:
Enhancing overall facial skin wellness: Augustinus Bader reveals The Face Oil - The Moodie Davitt Report - The Moodie Davitt Report

Cell Biology

University of Edinburgh spinout Cellinta will develop gene therapies for cancer – PharmaTimes

September 21, 2020 medical

A biotech company spun out of the University of Edinburgh will utilise research to develop new gene therapies to target different types of cancer.

The company, Cellinta Limited, was born out of research from scientists at the University of Edinburgh, and received funding through investments from SV Health Investors and Cancer Research UK.

The funding will be used to develop a pipeline of highly selective gene therapies targeting cancer stem cells in a variety of solid tumour types.

It will draw on research led by Professor Steven Pollard at the University of Edinburgh, which delved into stem cell biology, synthetic biology and cancer genomics.

Cellinta has entered into a collaborative research agreement with the University, and retains the option to license intellectual property developed from research conducted there.

Professor Pollard will join the Cellinta team as scientific founder and a senior adviser, while Dr Soraya Bekkali will take the helm as chief executive officer of the new company.

I am delighted to be leading such an exciting company, said Dr Bekkali.

Cellintas approach offers the opportunity to deliver combinations of therapies selectively to cancer stem cells, bypassing the limitations of traditional treatments which often target single genes or redundant signalling pathways, she added.

Meanwhile, Mike Ross managing partner at London-based SV Health Investors has been appointed chairman of Cellinta.

Cellinta represents a unique opportunity to build a leading company based on exciting and innovative science, with the potential to develop first-in-class therapies, said Ross.

We are delighted with the progress the company has made and extremely pleased to appoint Soraya, who has deep experience in gene therapy across various therapeutic areas, as CEO. We look forward supporting Cellinta in its progress as a pioneer in the field, he added.

See the original post here:
University of Edinburgh spinout Cellinta will develop gene therapies for cancer - PharmaTimes

Cell Biology

Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as…

September 21, 2020 medical

SAN FRANCISCO and SUZHOU, China, Sept. 20, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, jointly announce with Eli Lilly and Company ("Lilly", NYSE: LLY) that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements. The National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for this indication. Biomarker data analysis revealed that the MHC-II antigen presentation pathway played a key role in immunotherapy-chemotherapy combination. Higher gene expression of this pathway was significantly associated with longer progression-free survival (HR, 0.41; 95% CI, 0.23-0.76; P=0.0041) and could potentially serve as a predictive biomarker to select patients who can benefit from this regimen.

Professor Li ZHANG, Head of Department of Internal Medicine, Sun Yat-sen University Cancer Center, the primary investigator of the ORIENT-11 trial, stated: "Sintilimab in combination with pemetrexed and platinum chemotherapy showed improved efficacy and no new safety signals in locally advanced or metastatic nonsquamous NSCLC. These results will further our understanding of the performance of this combination in certain types of patients."

Dr. Wei XU, Vice President of New Drug Biology and Translational Medicine of Innovent, stated: "We were very pleased to release these biomarker results at the ESMO Virtual Congress 2020. MHC-II antigen presentation pathway might predict clinical efficacy of immunotherapy-chemotherapy. This finding could improve our understanding of the mechanism of action of this combination and provide a scientific rationale for future selection of patients who could benefit most."

Dr. Li WANG, Senior VP of Lilly China and Head of Lilly China Drug Development and Medical Affairs Center, stated: "Biomarker exploration is very important to advance cancer immunotherapy. We are very pleased that our discovery of a potential biomarker for immunotherapy will be shared at ESMO. I would like to thank all the investigators, scientists and patients involved in the trial."

About ORIENT-11 Trial

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating the efficacy and safety of TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements (ClinicalTrials.gov, NCT03607539). The primary endpoint is progression-free survival (PFS) assessed by Independent Radiographic Review Committee based on RECIST v1.1. The key secondary endpoints include overall survival (OS) and safety profile.

A total of 397 subjects have been enrolled in the ORIENT-11 trial and randomized in a 2:1 ratio to receive either TYVYT (sintilimab injection) 200mg or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy every three weeks for up to four cycles, followed by either TYVYT (sintilimab injection) or placebo plus ALIMTA (pemetrexed) maintenance therapy. The subjects will receive treatment until radiographic disease progression, unacceptable toxicity or any other conditions that require treatment discontinuation. Conditional crossover is permitted.

About nsqNSCLC

Lung cancer is a malignancy with the highest morbidity and mortality in China. NSCLC accounts for about 80 to 85 percent of lung cancer. Approximately 70 percent of NSCLC is locally advanced or metastatic at initial diagnosis, resulting in patients with having little to no chance of radical resection. Meanwhile, even after radical surgery, patients have a high chance of recurrence and eventually die from disease progression. About 70 percent of NSCLC in China is nonsquamous subtype and 50 percent of nsqNSCLC is without sensitizing EGFR mutations or ALK rearrangements. These patients do not respond well to targeted therapy and there are limited treatment options available to them.

About TYVYT (Sintilimab Injection)

TYVYT (sintilimab injection), an innovative drug with global quality standards jointly developed in China by Innovent and Lilly, has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy, and included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List (NRDL) in November 2019. In April 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with ALIMTA (pemetrexed) and platinum chemotherapy as first-line therapy in nonsquamous non-small cell lung cancer (NSCLC). In May 2020, TYVYT (sintilimab injection) monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma. In August 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with GEMZAR (gemcitabine for injection) and platinum chemotherapy as first-line therapy in squamous NSCLC.

TYVYT (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies for TYVYT (sintilimab injection) to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Meanwhile, Innovent is conducting clinical research studies on TYVYT (sintilimab injection) worldwide.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with three products, TYVYT (sintilimab injection), BYVASDA (bevacizumab injection) and SULINNO (adalimumab injection), on market, one asset under NDA review with priority review status, four assets in Phase 3 or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: http://www.innoventbio.com.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and lilly.com/newsroom.

About Innovent Biologics' strategic collaboration with Eli Lilly and Company

Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 a groundbreaking partnership between a Chinese pharmaceutical company and a multinational pharmaceutical company. Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China. In October 2015, the two companies announced the extension of their existing collaboration to include co-development of three additional oncology antibodies targeting oncology indications. In August 2019, Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. Its collaboration with Lilly indicates that Innovent has established a comprehensive level of cooperation between China's innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D, CMC, clinical development and commercialization. In August, 2020, Lilly and Innovent announced a global expansion of their strategic alliance for TYVYT (sintilimab injection), and Lilly will obtain an exclusive

license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets.

TYVYT (sintilimab injection, Innovent)

ALIMTA and GEMZAR are trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Disclaimer:

1. This indication is still under clinical trial, which hasn't been approved in China. 2. Innovent does not recommend any off-label usage.3. For medical and healthcare professional use only.

View original content:http://www.prnewswire.com/news-releases/innovent-and-lilly-release-biomarker-results-of-tyvyt-sintilimab-injection-in-combination-with-alimta-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-nonsquamous-non-small-cell-lung-cancer-at-esmo-virtual-co-301134412.html

SOURCE Innovent Biologics, Inc.

Company Codes: HongKong:1801, OTC-PINK:IVBIY

The rest is here:
Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as...

Cell Biology

A Drug Used to Treat Deadly Coronavirus Infections in Cats May Be an Effective Treatment Against COVID-19 – SciTechDaily

September 21, 2020 medical

In a search for COVID-19 treatments, researchers pursue a drug used on cats.

University of Alberta researchers worked with SLAC X-ray scientists to explore the potential of a feline coronavirus drug that may be effective against SARS-CoV-2.

Researchers at the University of Alberta have shown that a drug used to treat deadly coronavirus infections in cats could potentially be an effective treatment against SARS-CoV-2, the virus behind the global coronavirus pandemic. Theresults were published in the journal Nature Communications.

The study, which was aided by scientists at the U.S. Department of Energys SLAC National Accelerator Laboratory, paves the way for human clinical trials, which should begin soon, said Joanne Lemieux, a professor of biochemistry at the University of Alberta and the studys senior author.

Joanne Lemieux and a team at the University of Alberta found that a drug used in cats may help treat SARS-CoV-2 infections. Credit: Image courtesy Joanne Lemieux

This drug is very likely to work in humans, so were encouraged that it will be an effective treatment for COVID-19 patients, Lemieux said, although the clinical trials will need to run their course before anyone can be sure that the drug, a protease inhibitor called GC376, is both safe and effective for treating COVID-19 in humans.

In cats at least, GC376 works by interfering with a virus ability to replicate, thus ending an infection. Derivatives of this drug were first studied following the 2003 outbreak of severe acute respiratory syndrome (SARS), and it was further developed by veterinary researchers who showed it cures fatal feline affliction.

Lemieux and colleagues at the University of Alberta first tested two variants of the feline drug against SARS-CoV-2 protein in test tubes and with the live virus in human cell lines, then crystallized the drug variants in conjunction with virus proteins. Working with Silvia Russi, a crystallographer and beamline scientist for the Structural Molecular Biology program at SLACs Stanford Synchrotron Radiation Lightsource (SSRL), the researchers determined the orientation of the cat drug as it bound to an active site on a SARS-CoV-2 protein, revealing how it inhibits viral replication.

This will allow us to develop even more effective drugs, Lemieux said, and the team will continue to test modifications of the inhibitor to make it an even better fit inside the virus.

Aina Cohen, a SLAC senior scientist and co-division head of Structural Molecular Biology at SSRL, said she was excited by the drugs effectiveness and by SSRLs ability to help out. Until an effective vaccine can be developed and deployed, drugs like these add to our arsenal of COVID-19 treatments, she said. We are thrilled to learn of these important results and look forward to learning the outcome of clinical trials.

Reference: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication by Wayne Vuong, Muhammad Bashir Khan, Conrad Fischer, Elena Arutyunova, Tess Lamer, Justin Shields, Holly A. Saffran, Ryan T. McKay, Marco J. van Belkum, Michael A. Joyce, Howard S. Young, D. Lorne Tyrrell, John C. Vederas and M. Joanne Lemieux, 27 August 2020,Nature Communications.DOI: 10.1038/s41467-020-18096-2

The research was funded by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada. Extraordinary SSRL operations were supported in part by the DOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. SSRL is a DOE Office of Science user facility. The Structural Molecular Biology Program at SSRL is supported by the DOE Office of Science and by the National Institutes of Health, National Institute of General Medical Sciences.

Neuroscience

Global Alzheimer’s Platform Foundation Selects IXICO for Innovative Bio-Hermes Trial – PRNewswire

September 21, 2020 medical

LONDON, Sept. 21, 2020 /PRNewswire/ -- IXICO plc, the data analytics company delivering insights in neuroscience, today announced that it has been selected by the Global Alzheimer's Platform Foundation (GAP) to support GAP's planned Bio-Hermes trial. IXICO will apply its expertise to collect Positron Emission Tomography (PET) brain scans in qualifying imaging centres participating in Bio-Hermes and provide analysis of the scans.

Bio-Hermes' core purpose is development of a bio-sample database to investigate biomarkers on a head-to-head basis in conjunction with medical history elements. The Bio-Hermes trial will include 1,000 volunteers over the age of 60 screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD. Observational biomarker studies consistently suggest that amyloid deposition and tau deposition in neurofibrillary tangles in the brain may be the sentinel events in Alzheimer's Disease pathology. In the Bio-Hermes trial, Avid Pharmaceuticals' Amyvid will be used as the radioactive diagnostic agent to estimate -amyloid neuritic plaque density.

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"We are delighted to be selected by GAP as their prime choice for the analysis of PET scans in the Bio-Hermes trial. With a reinvigorated level of interest in Alzheimer's disease, we are excited about the prospects of long-term collaborationwith our colleagues at GAP who share our own commitment to reducing the time, cost, and risk for Alzheimer's Disease trials. The support provided by IXICO staff on Bio-Hermes is an important commercial development in enhancing IXICO's market position in neuroimaging for Alzheimer's Disease clinical trials."

John Dwyer, President of Global Alzheimer's Platform Foundation (GAP), commented:

"Our collaboration with IXICO for neuroimaging and AI is a key element of GAP's innovative Bio-Hermes trial, which is taking a novel approach to provide digital and blood biomarker results for comparison across cognitively normal and impaired individuals. We've also committed to ground-breaking levels of minority participation so that future treatment breakthroughs can benefit everyone impacted by Alzheimer's."

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer +44 (0)20 3763 7498

Global Alzheimer's Platform Foundation Media Pamela Larkin +1408-466-5952 or [emailprotected]

About the Global Alzheimer's Platform Foundation (GAP)

The Global Alzheimer's Platform Foundation (GAP) is a patient-centric nonprofit dedicated toacceleratingthe delivery of innovative therapies for neurological disorders by reducing thedurationand cost of clinical trials. Research centersacross the US and Canadaare part of the growing GAP Network (GAP-Net). GAP supportsGAP-Net research centers by assisting withstudy start up and recruitment activities,promotingdiversity in research studies, andofferingnational programsthatchampion brain health and the citizen scientists who make research possible.

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on http://www.IXICO.com.

SOURCE IXICO

https://ixico.com

See the original post:
Global Alzheimer's Platform Foundation Selects IXICO for Innovative Bio-Hermes Trial - PRNewswire

Neuroscience

How I taught neuroscience to primary pupils – and why – TES News

September 21, 2020 medical

At the beginning of each academic year, we teach our students about the brain.

When I first encountered this aspect of our curriculum, I doubted its value. Sure enough, despite teaching the different parts of the brain and making models of brains, the information failed to stick.

This is not an uncommon issue in primary school. All too often, we are guilty of expecting children to learn without really thinking about how this happens.

I first started thinking about this after overhearing a colleague speaking to a pupil about the fact that he had forgotten what they had studied the day before.

Why did that pupil forget what he did yesterday? What is happening in his brain so that he cannot recall that information when others can? That is when I started reading about neural pathways.

Put simply, neural pathways are connections between neurons in the brain, sending messages so that our body knows what to do when completing a task. They are also an excellent way of representing the learning process visually for students of all ages.

The more times we complete a task, the better we become at it because the message has been passed between the neurons more often: the pathways between neurons have become stronger.

I decided I wanted to teach my primary class about this concept to help them truly understand how their brain works and how learning is formed. I turned to technology to help.

We are lucky enough to have access to 10 Sphero robots in our school small plastic spheres that can be programmed or driven manually.

After drawing brains on paper and using blobs of paint for neurons, the pupils were tasked with driving these Spheros between the neurons to create neural pathways.

Using the Sphero Edu app, the children selected the manual drive mode and began trying to control the robots between the blobs of paint. The virtual joystick control is very simple, but the task is surprisingly difficult at first. The more accurate the students became, the more paint they were able to spread between the "neurons".

It was a lot of fun, of course, but my Year 5 students also came to appreciate the fact that the more times they drove between the neurons, the pathways we had created became stronger.

They could also see clearly for themselves how practising something helped them to improve, as their handling of the robots became more controlled the more they practised.

The stronger the pathways on the paper, the stronger the pathways in the learners brain.

The learning process was no longer as abstract to them.

Of course, the robots made this fun but if you dont have the same kind of access to technology, simply drawing lines or using string can also help to make this concept more concrete.

A shared piece of artwork, in which children take it in turns to draw or paint pathways between neurons, can become a useful display piece, which you can keep referring to throughout the year.

Turning the classroom into a brain and having children pass string between each other is another great way to make the concept more visual.

Throughout the year, I am able to refer back to these first-week activities when children are trying something new. It works especially well when pupils are finding something difficult and they are in need of a resilience boost.

Pupils understand more clearly why they are finding something challenging and are more likely to maintain a positive attitude towards their learning.

This strategy has worked equally well on my four-year-old daughter at home. At her age, it is common for children to become frustrated when trying new tasks.

Yet I found that she was very capable of understanding the concept of neural pathways.

Soon she started referring to the pathways herself, be it when she was trying to ride her bike, play tennis, read a new word or complete an addition problem.

If she is becoming stressed or frustrated, reminding her of the fact that she needs to strengthen the neural pathways always helps to calm her down and reassure her that she will be able to be successful with practice.

She is already developing a growth mindset, largely because of this understanding.

Overall, I have found speaking to children about this process and introducing them to metacognition a very effective tool in the classroom, and at home.

There is no reason why we should not be speaking to preschool children about their own learning process, building the foundations for them to become reflective, resilient learners.

And if this means that parents of preschoolers can avoid the odd frustrated tantrum along the way, all the better.

Luke Edeson is a primary teacher at HELPInternational School, Kuala Lumpur, Malaysia. He has taught internationally for 13 years

Visit link:
How I taught neuroscience to primary pupils - and why - TES News

Neuroscience

Higher Antioxidant Levels Linked to Protection Against Glaucoma – Technology Networks

September 21, 2020 medical

A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma. Their findings are published online in theJournal of Clinical Medicine, available here.

In general, glaucoma patients are vulnerable to increased intraocular pressure. However, a particular group of patients has no glaucomatous neurodegeneration despite high intraocular pressure -- patients with ocular hypertension.

The paper reports the discovery of a new mechanism to explain why patients with ocular hypertension do not have glaucoma. This is the first study evaluating oxidative stress and antioxidative agents in patients with normal-tension glaucoma and ocular hypertension during oxygen stress.

According to the American Academy of Ophthalmology, ocular hypertension is when the pressure inside the eye (intraocular pressure or IOP) is higher than normal.

The authors found that patients with ocular hypertension have increased antioxidant capacity and higher levels of anti-inflammatory, omega-3 derived chemical messengers involved in sustaining cell function in their plasma compared to patients with normal-tension glaucoma and age-matched controls. The abundance of these omega-3 fatty acid chemical messengers provides antioxidant defense, and as a consequence, potential resistance to elevated intraocular pressure and glaucomatous neurodegeneration by eliminating increases in systemic oxidative stress.

"The study opens avenues of therapeutic exploration highlighting the significance of the omega-3 fatty acid chemical messengers' antioxidant capacity as a potential diagnostic biomarker and as a novel treatment to prevent glaucomatous neurodegeneration," notes Dr. Nicolas G. Bazan, Boyd Professor, Ernest C. and Ivette C. Villere Chair of Retinal Degeneration, and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine.

Glaucoma is the most common cause of irreversible blindness. The sight-threatening disease is defined by a progressive loss of the innermost retinal neurons with corresponding visual field losses. Despite current treatments to lower the intraocular pressure, 15% of glaucoma patients go blind, and as many as 42% will lose sight in one eye.

Reference:

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:
Higher Antioxidant Levels Linked to Protection Against Glaucoma - Technology Networks